Osimertinib as adjuvant therapy in patients (pts) with stage IB-IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA

被引：0
|
作者：
Grohe, C. [1 ]
Herbst, R. S. [2 ,3 ]
Tsuboi, M. [4 ]
John, T. [5 ]
Majem, M. [6 ]
Goldman, J. W. [7 ]
Kim, S. -W. [8 ]
Marmol, D. [9 ]
Rukazenkov, Y. [10 ]
Wu, Y. -L. [11 ]
Engel-Riedel, W. [12 ]
机构：
[1] Evangel Lungenklin Berlin Buch, Klin Pneumol, Berlin, Germany
[2] Yale Sch Med, Med Oncol, New Haven, CT USA
[3] Yale Canc Ctr, New Haven, CT USA
[4] Natl Canc Ctr Hosp East, Dept Thorac Surg & Oncol, Chiba, Japan
[5] Austin Hlth, Dept Med Oncol, Heidelberg, Vic, Australia
[6] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain
[7] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[8] Asan Med Ctr, Dept Oncol, Seoul, South Korea
[9] AstraZeneca, Late Oncol Stat, Cambridge, England
[10] AstraZeneca, Oncol Res & Dev, Cambridge, England
[11] South China Univ Technol, Guangdong Lung Canc Inst, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci,Sch Med, Guangzhou, Peoples R China
[12] Klinikum Stadt Koln gGmbH, Cologne, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷 / SUPPL 4期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
166
引用
收藏
页码：138 / 138
页数：1
相关论文
共 50 条
  • [41] Postoperative Chemotherapy-Use and Results of the ADAURA-Study: Osimertinib as adjuvant Therapy in resected EGFR-mutated NSCLC Patients
    Grohe, C.
    Wu, Y. L.
    John, T.
    Majem, M.
    Goldman, J. W.
    Kim, S.
    Kato, T.
    Laktionov, K.
    Vu, H. V.
    Wang, Z.
    Lu, S.
    Lee, K.
    Akewanlop, C.
    Yu, C. J.
    De Marinis, F.
    Bonanno, L.
    Domine, M.
    Shepherd, F. A.
    Zeng, L.
    Atasoy, A.
    Herbst, R. S.
    Tsuboi, M.
    Engel-Riedel, W.
    PNEUMOLOGIE, 2021, 75 : S18 - S19
  • [42] Final follow-up (f/u) results from RADIANT: A randomized double blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection in patients (pts) with stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC).
    O'Brien, Mary E. R.
    Kelly, Karen
    Altorki, Nasser K.
    Eberhardt, Wilfried Ernst Erich
    Spigel, David R.
    Crino, Lucio
    Tsai, Chun-Ming
    Kim, Joo-Hang
    Cho, Eun Kyung
    Hoffman, Philip C.
    Keshavjee, Shaf
    Orlov, Sergey
    Serwatowski, Piotr
    Wang, Joe
    Foley, Margaret A.
    Horan, Julie D.
    Shepherd, Frances A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [43] Feasibility of adjuvant cisplatin and gemcitabine in patients who have undergone complete resection of stage IB-IIIA non-small cell lung cancer (NSCLC): Preliminary report of a feasibility trial in Japanese patients
    Yamaguchi, M.
    Takeo, S.
    Suemitsu, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [44] Osimertinib plus selumetinib for patients (pts) with EGFR-mutant (EGFRm) NSCLC following disease progression on an EGFR-TKI: Results from the Phase Ib TATTON study
    Ramalingam, Suresh S.
    Saka, Hideo
    Ahn, Myung-Ju
    Yu, Helena
    Horn, Leora
    Hida, Toyoaki
    Cantarini, Mireille
    Verheijen, Remy
    Wessen, Jonathan
    Oxnard, Geoffrey
    Ohe, Yuichiro
    CANCER RESEARCH, 2019, 79 (13)
  • [45] IMpower010: results from Asian patients in a phase 3 study of adjuvant atezolizumab in resected stage IB-IIIA NSCLC
    Kenmotsu, Hirotsugu
    Zhou, Caicun
    Altorki, Nasser
    Felip, Enriqueta
    Vallieres, Eric
    Sugawara, Shunichi
    Sakai, Hiroshi
    Saito, Haruhiro
    Tao, Min
    Kawaguchi, Koji
    Liu, Yunpeng
    Yu, Chong-Jen
    Wu, Qiong
    Lin, Huang
    Wu, Fan
    Bennett, Elizabeth
    Mcnally, Virginia
    Gitlitz, Barbara
    Wakelee, Heather
    ANNALS OF ONCOLOGY, 2022, 33 : S464 - S464
  • [46] Three-Year Safety, Tolerability, and Health- Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial
    John, Thomas
    Grohe, Christian
    Goldman, Jonathan W.
    Shepherd, Frances A.
    de Marinis, Filippo
    Kato, Terufumi
    Wang, Qun
    Su, Wu-Chou
    Choi, Jin Hyuk
    Sriuranpong, Virote
    Melotti, Barbara
    Fidler, Mary J.
    Chen, Jun
    Albayaty, Muna
    Stachowiak, Marta
    Taggart, Sarah
    Wu, Yi-Long
    Tsuboi, Masahiro
    Herbst, Roy S.
    Majem, Margarita
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (09) : 1209 - 1221
  • [47] The effect of savolitinib plus osimertinib on ctDNA clearance in patients with EGFR mutation positive (EGFRm) MET-amplified NSCLC in the TATTON study
    Hartmaier, Ryan
    Han, Ji-Youn
    Ahn, Myung-Ju
    Cho, Byoung Chul
    Cantarini, Mireille
    Frewer, Paul
    Frigault, Melanie M.
    Oxnard, Geoffrey
    CANCER RESEARCH, 2020, 80 (16)
  • [48] Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA
    Ramalingam, S.
    Reungwetwattana, T.
    Chewaskulyong, B.
    Dechaphunkul, A.
    Lee, K. H.
    Imamura, F.
    Nogami, N.
    Ohe, Y.
    Cheng, Y.
    Cho, B. C.
    Cho, E. K.
    Vansteenkiste, J. F.
    Voon, P. J.
    Zhou, C.
    Gray, J.
    Hodge, R.
    Rukazenkov, Y.
    Soria, J-C.
    ANNALS OF ONCOLOGY, 2017, 28
  • [49] LIBRETTO-432: A Placebo-Controlled Phase 3 Study of Adjuvant Selpercatinib in Stage IB-IIIA RET Fusion-Positive NSCLC
    Goldman, J.
    Besse, B.
    Wu, Y.
    Yang, J. C.
    Paz-Ares, L.
    Drilon, A.
    Johnson, M.
    Xia, M.
    Chao, B. H.
    Tsuboi, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S975 - S976
  • [50] A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?
    Lv, Chao
    An, Chao
    Feng, Qin
    Ma, Yuanyuan
    Li, Shaolei
    Wang, Jia
    Zhang, Jianzhi
    Wang, Xing
    Yan, Shi
    Fang, Jian
    Wang, Yinxiang
    Tan, Fenlai
    Yang, Yue
    CLINICAL LUNG CANCER, 2015, 16 (06) : E173 - E181
12345